1. Figure 4 Antinuclear antibodies and disease activity in SLE
Figure 4 | Antinuclear antibodies and disease activity in SLE. Levels of anti-DNA and anti-Sm antibodies were determined in the serum of a patient with systemic lupus erythematosus (SLE). Flares of disease activity resulted initially in treatment with cyclophosphamide and methylprednisolone, and subsequently with prednisone. In these studies, assay of anti-Sm antibodies (which bind to small nuclear riboproteins) was performed by passive haemagglutination (PHA), whereas anti-DNA antibody levels were determined by a filter-binding assay in which the presence of antibodies is detected by the capture of a radiolabelled DNA substrate with a nitrocellulose filter. In the absence of antibody binding, the DNA does not bind to the filter. Permission obtained from The Journal of Rheumatology © McCarty, G. A. et al. Independent expression of autoantibodies in systemic lupus erythematosus. J. Rheumatol. 9, 691–695 (1982).
Permission obtained from The Journal of Rheumatology © McCarty, G. A. et al. Independent expression of autoantibodies in systemic lupus erythematosus. J. Rheumatol. 9, 691–695 (1982)
Pisetsky, D. S. (2015) Anti-DNA antibodies — quintessential biomarkers of SLE
Nat. Rev. Rheumatol. doi: /nrrheum